Research study Program year 2020 Source: CMS Open Payments

RSV Mat-004

Research payments

$1,755,803

328 payments

Through program year 2020, $1,755,803 in research payments was reported against RSV Mat-004, across 328 payments, paid by GlaxoSmithKline, LLC..

Paid by: GlaxoSmithKline, LLC.
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2020	Research	$1,675,173	311
2019	Research	$80,630	17

Breakdown

Who paid Research payments · program years 2019–2020

GlaxoSmithKline, LLC. $1,755,803 328 payments

Who received the money Research payments · program years 2019–2020

Medpharmics LLC Organisation paid for research $641,850 126 payments
Ventavia Research Group LLC Organisation paid for research $586,388 67 payments
Gadolin Research LLC Organisation paid for research $139,192 23 payments
Join Clinical Trials LLC Organisation paid for research $101,152 21 payments
Matrix Clinical Research Organisation paid for research $94,996 28 payments
HWC Womens Research Center Organisation paid for research $74,866 23 payments
Asr LLC Organisation paid for research $56,270 17 payments
Sundance Clinical Research LLC Organisation paid for research $36,786 10 payments
Meridian Clinical Research LLC Organisation paid for research $14,805 11 payments
Matrix Clinical Research INC Organisation paid for research $9,500 2 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

8 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.